Cardiovascular Drug Interactions With Nirmatrelvir/Ritonavir in Patients With COVID-19

Nirmatrelvir/ritonavir use: Managing clinically significant drug‐drug interactions with transplant immunosuppressants

(2022) Nicholas W. Lange et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19

(2022) Jennifer Hammond et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effectiveness of Paxlovid in Reducing Severe COVID-19 and Mortality in High Risk Patients

(2022) Ronza Najjar-Debbiny et al.   CLINICAL INFECTIOUS DISEASES

Physiologically‐Based Pharmacokinetic Modeling‐Guided Dose Management of Oral Anticoagulants when Initiating Nirmatrelvir/Ritonavir (Paxlovid) for COVID‐19 Treatment

(2022) Ziteng Wang et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Drug Interactions Associated With Therapies for Pulmonary Arterial Hypertension

(2022) Shraddha Narechania et al.   JOURNAL OF PHARMACY TECHNOLOGY

Oral Nirmatrelvir and Ritonavir in Nonhospitalized Vaccinated Patients With Coronavirus Disease 2019 (COVID-19)

(2022) Sarju Ganatra et al.   CLINICAL INFECTIOUS DISEASES

Important interactions of immunosuppressants with experimental therapies for novel coronavirus disease (COVID-19)

(2020) Tanja R. Zijp et al.   THERAPEUTIC DRUG MONITORING

Lopinavir-Ritonavir in SARS-CoV-2 Infection and Drug-Drug Interactions with Cardioactive Medications

(2020) Shubham Agarwal et al.   CARDIOVASCULAR DRUGS AND THERAPY

Impact of Boosted Antiretroviral Therapy on the Pharmacokinetics and Efficacy of Clopidogrel and Prasugrel Active Metabolites

(2018) Niloufar Marsousi et al.   CLINICAL PHARMACOKINETICS

Atrial fibrillation and human immunodeficiency virus type-1 infection: a systematic review. Implications for anticoagulant and antiarrhythmic therapy

(2018) Daniele Pastori et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Transport properties of valsartan, sacubitril and its active metabolite (LBQ657) as determinants of disposition

(2017) Imad Hanna et al.   XENOBIOTICA

Lack of an Effect of Ritonavir Alone and Lopinavir-Ritonavir on the Pharmacokinetics of Fenofibric Acid in Healthy Volunteers

(2016) Lori A. Gordon et al.   PHARMACOTHERAPY

Drug Interactions Between Antiplatelet or Novel Oral Anticoagulant Medications and Antiretroviral Medications

(2014) Gregory Egan et al.   ANNALS OF PHARMACOTHERAPY

Managing drug interactions in HIV-infected adults with comorbid illness

(2014) Christine A. Hughes et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

Lack of Pharmacokinetic Interactions Between Pitavastatin and Efavirenz or Darunavir/Ritonavir

(2014) Carlos D. Malvestutto et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects

(2013) Wolfgang Mueck et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacology of the New P2Y12 Receptor Inhibitors: Insights on Pharmacokinetic and Pharmacodynamic Properties

(2013) Nicola Ferri et al.   DRUGS

Edoxaban versus Warfarin in Patients with Atrial Fibrillation

(2013) Robert P. Giugliano et al.   NEW ENGLAND JOURNAL OF MEDICINE

Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors

(2011) Robert A. Terkeltaub et al.   ARTHRITIS AND RHEUMATISM

Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies

(2010) Ron J. Keizer et al.   CLINICAL PHARMACOKINETICS

Interaction involving tadalafil and CYP3A4 inhibition by ritonavir

(2010) Pierre Loulergue et al.   SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES

Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1

(2010) P. Annaert et al.   XENOBIOTICA